Chronic myelogenous leukemia, a still unsolved problem: pitfalls and new therapeutic possibilities
Open Access
- 1 March 2019
- journal article
- review article
- Published by Taylor & Francis Ltd in Drug Design, Development and Therapy
- Vol. ume 13, 825-843
- https://doi.org/10.2147/dddt.s191303
Abstract
Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder of hematopoietic stem cells. At the molecular level, the disorder results from t(9;22)(q34;q11) reciprocal translocation between chromosomes, which leads to the formation of an oncogenic BCR–ABL gene fusion. Instead of progress in the understanding of the molecular etiology of CML and the development of novel therapeutic strategies, clinicians still face many challenges in the effective treatment of patients. In this review, we discuss the pathways of diagnosis and treatment of patients, as well as the problems appearing in the course of disease development. We also briefly refer to several aspects regarding the current knowledge on the molecular basis of CML and new potential therapeutic targets.Keywords
This publication has 69 references indexed in Scilit:
- Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-upLeukemia, 2012
- EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experienceBlood, 2012
- Genetic and Pharmacologic Inhibition of β-Catenin Targets Imatinib-Resistant Leukemia Stem Cells in CMLCell Stem Cell, 2012
- BCR-ABL suppresses autophagy through ATF5-mediated regulation of mTOR transcriptionBlood, 2011
- Selective targeting of the mTORC1/2 protein kinase complexes leads to antileukemic effects in vitro and in vivoBlood Cancer Journal, 2011
- Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS scoreBlood, 2011
- Chronic myeloid leukemia: mechanisms of blastic transformationJCI Insight, 2010
- The Double-Edged Sword of Autophagy Modulation in CancerClinical Cancer Research, 2009
- Targeting autophagy potentiates tyrosine kinase inhibitor–induced cell death in Philadelphia chromosome–positive cells, including primary CML stem cellsJCI Insight, 2009
- Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemiaNature, 2009